

# Steven Coutre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1638883/publications.pdf>

Version: 2024-02-01

100  
papers

11,849  
citations

101496

36  
h-index

40954

93  
g-index

100  
all docs

100  
docs citations

100  
times ranked

8457  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	13.9	1,427
2	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	13.9	1,261
3	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. <i>Blood</i> , 2002, 99, 3530-3539.	0.6	1,096
4	United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 3852-3860.	0.8	773
5	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	13.9	706
6	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 768-778.	5.1	676
7	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , 2007, 109, 3207-3213.	0.6	400
8	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1278-1291.	6.3	393
9	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. <i>Blood</i> , 2011, 117, 3294-3301.	0.6	353
10	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. <i>Blood</i> , 2007, 110, 2309-2315.	0.6	349
11	Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i> , 2010, 116, 3751-3757.	0.6	348
12	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. <i>Blood</i> , 2018, 131, 1910-1919.	0.6	339
13	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 65-75.	5.1	314
14	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	2.0	305
15	Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 1822-1828.	0.8	287
16	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017, 102, 1796-1805.	1.7	200
17	Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3015-3022.	0.8	181
18	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , the, 2017, 4, e114-e126.	2.2	181

#	ARTICLE	IF	CITATIONS
19	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019, 133, 2031-2042.	0.6	178
20	High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 676-683.	0.8	171
21	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. <i>Blood</i> , 2018, 131, 1415-1424.	0.6	160
22	Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. <i>Blood</i> , 2018, 131, 1704-1711.	0.6	122
23	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017, 129, 2612-2615.	0.6	111
24	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.	1.7	111
25	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. <i>Blood</i> , 2017, 129, 1763-1767.	0.6	78
26	SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 165, 504-509.	1.2	73
27	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	3.3	72
28	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. <i>Blood</i> , 2018, 131, 2331-2334.	0.6	64
29	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 648-657.e15.	0.2	62
30	Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2012, 13, 1096-1104.	5.1	58
31	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 417-423.	0.6	56
32	Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia. <i>Clinical Infectious Diseases</i> , 2022, 74, 1659-1668.	2.9	56
33	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. <i>British Journal of Haematology</i> , 2017, 178, 286-291.	1.2	55
34	Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110Î, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 1777-1777.	0.6	54
35	ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 31-31.	0.6	47
36	Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. <i>Blood Advances</i> , 2018, 2, 1946-1956.	2.5	40

#	ARTICLE	IF	CITATIONS
37	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. <i>British Journal of Haematology</i> , 2018, 182, 504-512.	1.2	37
38	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. <i>British Journal of Haematology</i> , 2015, 171, 471-477.	1.2	36
39	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.	0.6	36
40	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE-1 Trial. <i>Blood</i> , 2014, 124, 327-327.	0.6	33
41	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 803-813.e7.	0.2	32
42	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. <i>Blood</i> , 2019, 134, 33-33.	0.6	29
43	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	2.0	27
44	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	0.6	27
45	Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. <i>Blood</i> , 2015, 126, 715-715.	0.6	26
46	Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. <i>British Journal of Haematology</i> , 2007, 136, 379-392.	1.2	25
47	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 3331-3331.	0.6	24
48	Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 957-960.	2.0	22
49	A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 1987-1987.	0.6	22
50	Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. <i>Blood</i> , 2018, 131, 2782-2788.	0.6	18
51	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018, 132, 6-6.	0.6	18
52	Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. <i>Seminars in Cancer Biology</i> , 2004, 14, 307-315.	4.3	17
53	Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.. <i>Blood</i> , 2009, 114, 788-788.	0.6	17
54	Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?. <i>Cancer</i> , 2013, 119, 1186-1194.	2.0	16

#	ARTICLE	IF	CITATIONS
55	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. <i>Blood</i> , 2015, 126, LBA-6-LBA-6.	0.6	13
56	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	3.3	12
57	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE <sup>TM</sup> Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 4696-4696.	0.6	12
58	Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7023-7023.	0.8	12
59	CNS Relapse in Acute Promyelocytic Leukemia: Incidence, Management and Outcome. <i>Blood</i> , 2012, 120, 1489-1489.	0.6	12
60	Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2018, 132, 3133-3133.	0.6	11
61	Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant. <i>Blood</i> , 2014, 124, 4697-4697.	0.6	11
62	Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy. <i>Blood</i> , 2017, 130, 834-834.	0.6	11
63	Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7510-7510.	0.8	11
64	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 184-188.	1.2	10
65	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. <i>Blood</i> , 2014, 124, 1990-1990.	0.6	10
66	Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. <i>Seminars in Cancer Biology</i> , 2004, 14, 23-31.	4.3	9
67	Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18030-e18030.	0.8	9
68	Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710.. <i>Blood</i> , 2006, 108, 566-566.	0.6	7
69	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	0.6	7
70	Long-term follow-up of a phase 1b trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7011-7011.	0.8	7
71	Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.. <i>Blood</i> , 2009, 114, 1015-1015.	0.6	6
72	A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results. <i>Blood</i> , 2010, 116, 2516-2516.	0.6	6

#	ARTICLE	IF	CITATIONS
73	Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. <i>Blood</i> , 2014, 124, 1186-1186.	0.6	6
74	Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2018, 103, e249-e251.	1.7	5
75	Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies. <i>Blood</i> , 2010, 116, 3286-3286.	0.6	5
76	ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7566-TPS7566.	0.8	5
77	Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.. <i>Blood</i> , 2006, 108, 3770-3770.	0.6	4
78	Performance of the Karius Plasma Next Generation Sequencing Test in Determining the Etiologic Diagnosis of Febrile Neutropenia: Results from a Pilot Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, S613-S614.	0.4	3
79	The Impact of Distance to Treatment Center on the Outcome of AML. <i>Blood</i> , 2010, 116, 4742-4742.	0.6	3
80	Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7012-7012.	0.8	3
81	Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8532-8532.	0.8	3
82	Myelodysplastic syndromes: disease overview and therapy options. <i>Managed Care</i> , 2008, 17, 3-8.	0.3	3
83	Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. <i>JAAD Case Reports</i> , 2020, 6, 819-821.	0.4	2
84	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015, 126, 495-495.	0.6	2
85	Safety and tolerability of the combination of ATRA + arsenic trioxide (ATO) + gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7016-7016.	0.8	2
86	Classification and Risk Stratification for Acute Promyelocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, S127-S129.	0.2	1
87	Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.. <i>Blood</i> , 2009, 114, 3088-3088.	0.6	1
88	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). <i>Blood</i> , 2010, 116, 1376-1376.	0.6	1
89	Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses. <i>Blood</i> , 2014, 124, 3751-3751.	0.6	1
90	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7510-7510.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL. Blood, 2015, 126, 4153-4153.	0.6	1
92	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG) Tj ETQq0 00fgBT /Overlock 10	0.6	1
93	Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML. Blood, 2020, 136, 36-37.	0.6	1
94	A one-two punch with VO KOs CLL. Blood, 2019, 133, 2737-2738.	0.6	0
95	Pooled Safety Summary for Patients Treated with the CD22-Directed Cytotoxin Moxetumomab Pasudotox-tdfk. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S275.	0.2	0
96	A Phase I Study of a Novel Human Monoclonal Antibody (mAb216) with Chemotherapy for the Treatment of Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 2831-2831.	0.6	0
97	A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). Blood, 2010, 116, 3288-3288.	0.6	0
98	Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Statusâ€“Based Treatment Stratification. Blood, 2010, 116, 3313-3313.	0.6	0
99	Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.. Journal of Clinical Oncology, 2019, 37, 7014-7014.	0.8	0
100	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leukemia and Lymphoma, 2022, 63, 1580-1588.	0.6	0